Macquarie reviews forecasts and ahead of the annual meeting, moderating FY23 and FY24 estimates as the outlook for respiratory hospitalisation eases. The broker suspects a sequential improvement in Fisher & Paykel Healthcare's sales force productivity should lift clinical adoption, as destocking is currently obscuring the picture on device utilisation. Moreover, the broker continues to believe the market is under appreciating the medium-term hospital potential. Meanwhile, the outlook for home care appears to be improving as patient diagnosis rates improve. The Outperform rating is retained and the target price decreases to NZ$26.66 from NZ$27.46.
Only somebody who earns a salary and doesn't suffer if they are wrong could write and believe this IMO - lol
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)